Horizon's Genmab drug gets blockbuster status

After the first nine months of 2021, sales of Tepezza have crossed the important USD 1bn annual sales threshold.

Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix

Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.

This strong growth means that the company has now fulfilled its ambition of making Tepezza a blockbuster drug in 2021. Q3 sales alone totaled USD 610m, bringing sales for the first nine months of the year up to USD 1072m.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs